+

WO1999036536A3 - Methods and compositions to alter tissue susceptibility to immune injury, to programmed cell death, and to clearance by the reticuloendothelial system - Google Patents

Methods and compositions to alter tissue susceptibility to immune injury, to programmed cell death, and to clearance by the reticuloendothelial system Download PDF

Info

Publication number
WO1999036536A3
WO1999036536A3 PCT/US1999/001087 US9901087W WO9936536A3 WO 1999036536 A3 WO1999036536 A3 WO 1999036536A3 US 9901087 W US9901087 W US 9901087W WO 9936536 A3 WO9936536 A3 WO 9936536A3
Authority
WO
WIPO (PCT)
Prior art keywords
clearance
compositions
methods
cell death
programmed cell
Prior art date
Application number
PCT/US1999/001087
Other languages
French (fr)
Other versions
WO1999036536A9 (en
WO1999036536A2 (en
Inventor
Peter J Sims
Therese Wiedmer
Ji Zhao
Original Assignee
Blood Center Res Found Inc
Peter J Sims
Therese Wiedmer
Ji Zhao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blood Center Res Found Inc, Peter J Sims, Therese Wiedmer, Ji Zhao filed Critical Blood Center Res Found Inc
Priority to AU23262/99A priority Critical patent/AU2326299A/en
Priority to EP99903179A priority patent/EP1047779A2/en
Publication of WO1999036536A2 publication Critical patent/WO1999036536A2/en
Publication of WO1999036536A9 publication Critical patent/WO1999036536A9/en
Publication of WO1999036536A3 publication Critical patent/WO1999036536A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A method for extending the viability of mammalian cells or tissues comprising the step of inhibiting the expression of native PL scramblase within the cell or tissue is disclosed. In another embodiment of the invention, a method of decreasing the viability, metastatic or invasive potential of cancer cells, cancerous tissue, or viral-infected cell by causing increased expression or activity of PL scramblase protein within the cell or tissue is disclosed.
PCT/US1999/001087 1998-01-20 1999-01-19 Methods and compositions to alter tissue susceptibility to immune injury, to programmed cell death, and to clearance by the reticuloendothelial system WO1999036536A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU23262/99A AU2326299A (en) 1998-01-20 1999-01-19 Methods and compositions to alter tissue susceptibility to immune injury, to programmed cell death, and to clearance by the reticuloendothelial system
EP99903179A EP1047779A2 (en) 1998-01-20 1999-01-19 Methods and compositions to alter tissue susceptibility to immune injury, to programmed cell death, and to clearance by the reticuloendothelial system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7195098P 1998-01-20 1998-01-20
US60/071,950 1998-01-20

Publications (3)

Publication Number Publication Date
WO1999036536A2 WO1999036536A2 (en) 1999-07-22
WO1999036536A9 WO1999036536A9 (en) 1999-11-04
WO1999036536A3 true WO1999036536A3 (en) 1999-12-09

Family

ID=22104619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/001087 WO1999036536A2 (en) 1998-01-20 1999-01-19 Methods and compositions to alter tissue susceptibility to immune injury, to programmed cell death, and to clearance by the reticuloendothelial system

Country Status (3)

Country Link
EP (1) EP1047779A2 (en)
AU (1) AU2326299A (en)
WO (1) WO1999036536A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139359A1 (en) * 2001-12-04 2003-07-24 Isis Pharmaceuticals Inc. Antisense modulation of phospholipid scramblase 3 expression
US20030044979A1 (en) * 2001-04-05 2003-03-06 Isis Pharmaceuticals Inc. Antisense modulation of phospholipid scramblase I expression
IL147812A0 (en) * 2001-03-16 2002-08-14 N S T Neurosurvival Technologi Method for targeting chemical compounds to cells and pharmaceutical compositions used therein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037225A1 (en) * 1996-04-02 1997-10-09 Blood Center Research Foundation A PROTEIN PREPARATION THAT MEDIATES Ca2+-DEPENDENT TRANSBILAYER MOVEMENT OF PLASMA MEMBRANE PHOSPHOLIPID AND INHIBITORS THEREOF
WO1999019352A2 (en) * 1997-10-10 1999-04-22 Blood Center Research Foundation Methods and compositions to alter the cell surface expression of phosphatidylserine and other clot-promoting plasma membrane phospholipids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037225A1 (en) * 1996-04-02 1997-10-09 Blood Center Research Foundation A PROTEIN PREPARATION THAT MEDIATES Ca2+-DEPENDENT TRANSBILAYER MOVEMENT OF PLASMA MEMBRANE PHOSPHOLIPID AND INHIBITORS THEREOF
WO1999019352A2 (en) * 1997-10-10 1999-04-22 Blood Center Research Foundation Methods and compositions to alter the cell surface expression of phosphatidylserine and other clot-promoting plasma membrane phospholipids

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
B VERHOEVEN ET AL: "Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 182, no. 182, 1995, pages 1597 - 1601, XP002099796, ISSN: 0022-1007 *
BRATTON, D.: "Polyamine inhibition of transbilayer movement of plasma membrane phospholipids in the erythrocyte ghost", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 269, 9 September 1994 (1994-09-09), pages 22517 - 22523, XP002107581, ISSN: 0021-9258 *
E F SMEETS ET AL: "Calcium-induced transbilayer scrambling of fluorescent phopholipids analogs in platelets and erythrocytes", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1195, no. 1195, 1994, pages 281 - 286, XP002099795, ISSN: 0006-3002 *
STOUT J G ET AL: "Change in conformation of plasma membrane phospholipid scramblase induced by occupancy of its Ca2+ binding site.", BIOCHEMISTRY, (1998 OCT 20) 37 (42) 14860-6., XP002107584 *
UTSUGI ET AL: "Elevated Expression of Phosphatidylseine in the Outer Membrane Leaflet of Human Tumor Cells and Recognition by Activated Human Blood Monocytes", CANCER RESEARCH, vol. 51, no. 51, 1 June 1991 (1991-06-01), pages 3062 - 3066, XP002101466 *
ZHAO J ET AL: "Palmitoylation of phospholipid scramblase is required for normal function in promoting Ca2+-activated transbilayer movement of membrane phospholipids.", BIOCHEMISTRY, (1998 MAY 5) 37 (18) 6361-6., XP002107583 *
ZHAO, J. ET AL.: "Level of expression of phospholipid scramblase regulates induced movement of phosphatidylserine to the cell surface", JOURNAL OF BIOLOGICAL CHEMISTRY, (1998 MAR 20) 273 (12) 6603-6., XP002115839 *
ZHOU Q ET AL: "Identity of a conserved motif in phospholipid scramblase that is required for Ca2+-accelerated transbilayer movement of membrane phospholipids.", BIOCHEMISTRY, (1998 FEB 24) 37 (8) 2356-60., XP002098910 *
ZHOU Q ET AL: "Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids.", JOURNAL OF BIOLOGICAL CHEMISTRY, (1997 JUL 18) 272 (29) 18240-4., XP002098868 *
ZHOU, Q. ET AL.: "Sequences of human and mouse plasma membrane PL scramblase reveal residues required for Ca2+-induced reorganization of membrane phospholipids.", MOLECULAR BIOLOGY OF THE CELL, (NOV., 1997) VOL. 8, NO. SUPPL., PAGE 292A; ABSTRACT 1693., XP002107580 *
ZWAAL, R. & SCHROIT, A.: "Pathophysiologic implications of membrane phospholipid asymmetry in blood cells", BLOOD, vol. 89, 15 February 1997 (1997-02-15), pages 1121 - 1132, XP002107582, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO1999036536A9 (en) 1999-11-04
EP1047779A2 (en) 2000-11-02
AU2326299A (en) 1999-08-02
WO1999036536A2 (en) 1999-07-22

Similar Documents

Publication Publication Date Title
WO2001051633A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1146046A3 (en) Pyropheophorbides and their use in photodynamic therapy
CN101496774A (en) Cosmetic composition comprising ascorbic acid 2-glucoside and ergothioneine
EP0945814A3 (en) Method and system for providing artificial intelligence for planning and risk assessment of surgical paths
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
WO2000015247A3 (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
CA2098113A1 (en) Substances of polypeptide nature useful in human therapy
BR9903750A (en) Use of at least one rosacea extract of the genus sanguisorba and cosmetic process of pigmentation of the skin and / or hair and / or hair
ATE303127T1 (en) USE OF AT LEAST ONE IRVINGIA GABONENSIS EXTRACT IN COSMETIC AND/OR PHARMACEUTICAL PRODUCTS
WO1999036536A3 (en) Methods and compositions to alter tissue susceptibility to immune injury, to programmed cell death, and to clearance by the reticuloendothelial system
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000047231A3 (en) Novel antisense inhibition of rad51
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
TW200716979A (en) Screening methods for compounds that affect melanogenesis
EP1696028A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2003079884A3 (en) Methods for diagnosis and prognosis of cancer
Hamdy et al. Some biochemical and physical changes occurring in experimentally-inflicted poultry bruises.
EP1046397A3 (en) Novel bioactivating substance
ZA200108299B (en) Fried pet treats.
WO2001054707A3 (en) Modification of surface proteins by aminopeptidase inhibitors
AU7944700A (en) Bio-artificial substrate for the production of animal and, in particular, human tissues and organs
WO2001094409A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002047534A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003068160A3 (en) Use of insulin-like growth factor binding protein 3 (igf-bp3) for inhibition of tumor growth
WO2001098339A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/16-16/16, DRAWINGS, REPLACED BY NEW PAGES 1/20-20/20; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1999903179

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09600535

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999903179

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999903179

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载